Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bioventus Inc (BVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BVS (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 79.57% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 619.89M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 366064 | Beta 0.86 | 52 Weeks Range 3.90 - 14.38 | Updated Date 04/2/2025 |
52 Weeks Range 3.90 - 14.38 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate 0.085 | Actual 0.15 |
Profitability
Profit Margin -5.85% | Operating Margin (TTM) 7.23% |
Management Effectiveness
Return on Assets (TTM) 3.24% | Return on Equity (TTM) -21.55% |
Valuation
Trailing PE - | Forward PE 13.87 | Enterprise Value 913934853 | Price to Sales(TTM) 1.08 |
Enterprise Value 913934853 | Price to Sales(TTM) 1.08 | ||
Enterprise Value to Revenue 1.57 | Enterprise Value to EBITDA 22.93 | Shares Outstanding 66156900 | Shares Floating 34473682 |
Shares Outstanding 66156900 | Shares Floating 34473682 | ||
Percent Insiders 11.47 | Percent Institutions 69.87 |
Analyst Ratings
Rating 4.33 | Target Price 15 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bioventus Inc
Company Overview
History and Background
Bioventus Inc. was founded in 2012 as a spin-off from Smith & Nephew's biologics division. It focuses on developing and marketing orthobiologic solutions.
Core Business Areas
- Active Healing Therapies: Focuses on products that promote bone fracture healing and bone regeneration. Examples include bone graft substitutes and bone stimulation devices.
- Pain Treatment: Offers non-surgical pain management solutions, including hyaluronic acid (HA) injections for osteoarthritis and other pain therapies.
- Surgical Solutions: Encompasses a range of surgical products used in orthopedic procedures, aimed at improving patient outcomes.
Leadership and Structure
Ken Reali serves as the Chief Executive Officer. The organizational structure comprises various departments, including R&D, Sales & Marketing, Operations, and Finance, each headed by senior executives.
Top Products and Market Share
Key Offerings
- DUROLANE: A single-injection hyaluronic acid (HA) product for osteoarthritis pain management. Competitors include other HA injection brands such as Synvisc (Sanofi) and Euflexxa (Ferring Pharmaceuticals). Estimated to be 11% of the global HA osteoarthritis market share.
- EXOGEN: An ultrasound bone healing system designed to accelerate the healing of fractures. Competitors include Orthofix and Zimmer Biomet in the bone stimulation market. Market share in the bone stimulator segment is approximately 25%.
- OSTEOAMP: A family of bone graft substitutes for orthopedic surgeries. It competes with Medtronic's INFUSE and Stryker's bone graft products.
Market Dynamics
Industry Overview
The orthobiologics market is experiencing growth due to the aging population, increasing incidence of osteoarthritis, and advancements in regenerative medicine.
Positioning
Bioventus Inc. holds a strong position in the non-surgical pain management and bone healing segments, with competitive advantages in its established product portfolio and global distribution network.
Total Addressable Market (TAM)
The orthobiologics TAM is estimated to be in the range of $7 billion to $8 billion USD. Bioventus is positioned to capture a portion of this market through its product offerings and expansion strategies.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Global distribution network
- Strong brand recognition in certain segments
- Focus on non-surgical pain management solutions
- Innovative products
Weaknesses
- Dependence on key products
- Limited market share in some segments
- Higher operating expenses due to R&D and market penetration costs
- Debt burden
Opportunities
- Expanding product portfolio through acquisitions and new product development
- Increasing market penetration in emerging markets
- Leveraging technological advancements in regenerative medicine
- Partnerships and collaborations
Threats
- Competition from larger players with greater resources
- Regulatory changes impacting product approvals and reimbursement
- Pricing pressure from healthcare providers
- Economic downturn affecting elective procedures
- Patent expirations
Competitors and Market Share
Key Competitors
- SNY
- ZBH
- MDTC
- ORTH
Competitive Landscape
Bioventus faces strong competition from larger medical device companies. Its advantage lies in its focus on orthobiologics and innovative product portfolio, while its disadvantages include its smaller size and limited resources compared to its competitors.
Major Acquisitions
Misonix
- Year: 2021
- Acquisition Price (USD millions): 518
- Strategic Rationale: Expanded Bioventus's surgical solutions portfolio with ultrasonic medical devices.
CartiHeal
- Year: 2023
- Acquisition Price (USD millions): 450
- Strategic Rationale: Expanded Bioventus's product line with Agili-C implant for cartilage regeneration
Growth Trajectory and Initiatives
Historical Growth: Bioventus has shown moderate revenue growth over the past few years, driven by acquisitions and market expansion.
Future Projections: Analysts project continued revenue growth driven by expansion into new markets and increasing adoption of their products. EPS is expected to increase in coming years.
Recent Initiatives: Recent initiatives include acquisitions of companies with complementary products, expansion into new markets, and investments in R&D to develop new products.
Summary
Bioventus is a player in the orthobiologics market with a growing portfolio and distribution network. Their strengths lie in pain management and bone healing solutions, but debt remains a concern. The company's future growth relies on market penetration, successful product development, and strategic acquisitions. The industry's competitive landscape and regulatory environment pose ongoing challenges.
Similar Companies
SNY
Sanofi ADR
SNY
Sanofi ADR
ZBH
Zimmer Biomet Holdings Inc
ZBH
Zimmer Biomet Holdings Inc
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is based on estimates and may vary. All financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioventus Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2021-02-11 | President, CEO & Director Mr. Robert E. Claypoole | ||
Sector Healthcare | Industry Medical Devices | Full time employees 930 | Website https://www.bioventus.com |
Full time employees 930 | Website https://www.bioventus.com | ||
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprises of various intra-articular and hyaluronic acid injections, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise ultrasonic products offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; bone graft substitutes, a portfolio includes various products that facilitate optimal bone fusion. The company's product includes, nexus, an ultrasonic surgical system, an ultrasonic surgical platform; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite, a handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies, which includes minimally invasive fracture treatments and rehabilitation products. Its products include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.